The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Targeting Oncogenic Mutant p53 for Cancer Therapy
Open accessAbstract
Among genetic alterations in human cancers, mutations in the tumor suppressor p53 gene are the most common, occurring in over 50% of human cancers. The majority of p53 mutations are missense mutations and result in the accumulation of dysfunctional p53 protein in tumors. These mutants frequently have oncogenic gain-of-function activities and exacerbate malignant properties of cancer cells, such as metastasis and drug resistance. Increasing evidence reveals that stabilization of mutant p53 in tumors is crucial for its oncogenic activities, while depletion of mutant p53 attenuates malignant properties of cancer cells. Thus, mutant p53 is an attractive druggable target for cancer therapy. Different approaches have been taken to develop small-molecule compounds that specifically target mutant p53. These include compounds that restore wild-type conformation and transcriptional activity of mutant p53, induce depletion of mutant p53, inhibit downstream pathways of oncogenic mutant p53, and induce synthetic lethality to mutant p53. In this review article, we comprehensively discuss the current strategies targeting oncogenic mutant p53 in cancers, with special focus on compounds that restore wild-type p53 transcriptional activity of mutant p53 and those reducing mutant p53 levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647
The cellular thermal shift assay for evaluating drug target interactions in cells
Jafari, R., Almqvist, H., Axelsson, H., Ignatushchenko, M., Lundbäck, T., Nordlund, P., & Molina, D. M. (2014) · Nature Protocols · doi:10.1038/nprot.2014.138 · Cited by 1,474
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Arsenic Exposure and Toxicology: A Historical Perspective
Hughes, M. F., Beck, B. D., Chen, Y., Lewis, A. S., & Thomas, D. J. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr184 · Cited by 1,312
Target identification using drug affinity responsive target stability (DARTS)
Lomenick, B., Hao, R., Jonai, N., Chin, R. M., Aghajan, M., Warburton, S., Wang, J., Wu, R. P., Gomez, F., Loo, J. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910040106 · Cited by 1,095
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Rivlin, N., Brosh, R., Oren, M., & Rotter, V. (2011) · Genes & Cancer · doi:10.1177/1947601911408889 · Cited by 1,033
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865
Degradation of oxidized proteins by the 20S proteasome
Davies, K. J. A. (2001) · Biochimie · doi:10.1016/s0300-9084(01)01250-0 · Cited by 855
Beclin1 Controls the Levels of p53 by Regulating the Deubiquitination Activity of USP10 and USP13
Liu, J., Xia, H., Kim, M., Xu, L., Li, Y., Zhang, L., Cai, Y., Norberg, H. V., Zhang, T., Furuya, T., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.037 · Cited by 820
Pharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 799
Metabolic control of YAP and TAZ by the mevalonate pathway
Sorrentino, G., Ruggeri, N., Specchia, V., Cordenonsi, M., Mano, M., Dupont, S., Manfrin, A., Ingallina, E., Sommaggio, R., Piazza, S., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2936 · Cited by 776
Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors
Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 750
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719
Structural Biology of the Tumor Suppressor p53
Joerger, A. C., & Fersht, A. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.060806.091238 · Cited by 693
USP10 Regulates p53 Localization and Stability by Deubiquitinating p53
Yuan, J., Luo, K., Zhang, L., Cheville, J. C., & Lou, Z. (2010) · Cell · doi:10.1016/j.cell.2009.12.032 · Cited by 637 · cited 1×
“Since USP10 also deubiquitinates wild-type p53, Spautin-1 promotes degradation of wild-type p53 (89, 90).”
BackgroundDiscovery and development of SAHA as an anticancer agent
Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210204 · Cited by 626
Vaseva, A. V., & Moll, U. M. (2009) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2008.10.005 · Cited by 618
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway
Kung, A. L., Zabludoff, S. D., France, D. S., Freedman, S. J., Tanner, E. A., Vieira, A., Cornell-Kennon, S., Lee, J., Wang, B., Wang, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.009 · Cited by 480
p53 Research: The Past Thirty Years and the Next Thirty Years
Lane, D., & Levine, A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000893 · Cited by 454
UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53
Wang, Q., Fan, S., Eastman, A., Worland, P. J., Sausville, E. A., & O'Connor, P. M. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.14.956 · Cited by 453
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 387
The inherent instability of mutant p53 is alleviated by Mdm2 or p16 INK4a loss
Terzian, T., Suh, Y.-A., Iwakuma, T., Post, S. M., Neumann, M., Lang, G. A., Van Pelt, C. S., & Lozano, G. (2008) · Genes & Development · doi:10.1101/gad.1662908 · Cited by 357
Self-citationImproving survival by exploiting tumour dependence on stabilized mutant p53 for treatment
Alexandrova, E. M., Yallowitz, A. R., Li, D., Xu, S., Schulz, R., Proia, D. A., Lozano, G., Dobbelstein, M., & Moll, U. M. (2015) · Nature · doi:10.1038/nature14430 · Cited by 354
Selivanova, G., Iotsova, V., Okan, I., Fritsche, M., Ström, M., Groner, B., Grafström, R. C., & Wiman, K. G. (1997) · Nature Medicine · doi:10.1038/nm0697-632 · Cited by 343
Li, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336
Allele-Specific p53 Mutant Reactivation
Yu, X., Vazquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 319
Li, D., Marchenko, N. D., Schulz, R., Fischer, V., Velasco-Hernandez, T., Talos, F., & Moll, U. M. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0534 · Cited by 297
Sur, S., Pagliarini, R., Bunz, F., Rago, C., Diaz, L. A., Kinzler, K. W., Vogelstein, B., & Papadopoulos, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813333106 · Cited by 295
Friedler, A., Hansson, L. O., Veprintsev, D. B., Freund, S. M. V., Rippin, T. M., Nikolova, P. V., Proctor, M. R., Rüdiger, S., & Fersht, A. R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241629998 · Cited by 268
Targeting p53 for Novel Anticancer Therapy
Wang, Z., & Sun, Y. (2010) · Translational Oncology · doi:10.1593/tlo.09250 · Cited by 250
Small molecule induced reactivation of mutant p53 in cancer cells
Liu, X., Wilcken, R., Joerger, A. C., Chuckowree, I. S., Amin, J., Spencer, J., & Fersht, A. R. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt305 · Cited by 234
p53 as a target for the treatment of cancer
Duffy, M. J., Synnott, N. C., McGowan, P. M., Crown, J., O’Connor, D., & Gallagher, W. M. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.004 · Cited by 229
Ubiquitination and Degradation of Mutant p53
Lukashchuk, N., & Vousden, K. H. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00050-07 · Cited by 223
Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53
Wassman, C. D., Baronio, R., Demir, Ö., Wallentine, B. D., Chen, C.-K., Hall, L. V., Salehi, F., Lin, D.-W., Chung, B. P., Wesley Hatfield, G., et al. (2013) · Nature Communications · doi:10.1038/ncomms2361 · Cited by 223
Hui, L., Zheng, Y., Yan, Y., Bargonetti, J., & Foster, D. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209735 · Cited by 218
Krug, L. M., Kindler, H. L., Calvert, H., Manegold, C., Tsao, A. S., Fennell, D., Öhman, R., Plummer, R., Eberhardt, W. E. E., Fukuoka, K., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70056-2 · Cited by 215
Martinez, L. A., Naguibneva, I., Lehrmann, H., Vervisch, A., Tchénio, T., Lozano, G., & Harel-Bellan, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222406899 · Cited by 210
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
Wang, Y., Li, J., Booher, R. N., Kraker, A. J., Lawrence, T. S., Leopold, W. R., & Sun, Y. (2001) · PubMed · Cited by 210
Transcription regulation by mutant p53
Weisz, L., Oren, M., & Rotter, V (2007) · Oncogene · doi:10.1038/sj.onc.1210294 · Cited by 207
Chaperone-mediated autophagy degrades mutant p53
Vakifahmetoglu-Norberg, H., Kim, M., Xia, H.-G., Iwanicki, M. P., Ofengeim, D., Coloff, J. L., Pan, L., Ince, T. A., Kroemer, G., Brugge, J. S., et al. (2013) · Genes & Development · doi:10.1101/gad.220897.113 · Cited by 203
Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs
Bykov, V. J. N., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501664200 · Cited by 202
Nechushtan, H., Hamamreh, Y., Nidal, S., Gotfried, M., Baron, A., Shalev, Y. I., Nisman, B., Peretz, T., & Peylan-Ramu, N. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0424 · Cited by 202
Velu, C. S., Niture, S. K., Doneanu, C. E., Pattabiraman, N., & Srivenugopal, K. S. (2007) · Biochemistry · doi:10.1021/bi700425y · Cited by 201
Synthetic lethality: exploiting the addiction of cancer to DNA repair
Shaheen, M., Allen, C., Nickoloff, J. A., & Hromas, R. (2011) · Blood · doi:10.1182/blood-2011-01-313734 · Cited by 198
Kravchenko, J. E., Ilyinskaya, G. V., Komarov, P. G., Agapova, L. S., Kochetkov, D. V., Strom, E., Frolova, E. I., Kovriga, I., Gudkov, A. V., Feinstein, E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802091105 · Cited by 191
Geldanamycin selectively destabilizes and conformationally alters mutated p53.
Blagosklonny, M. V., Toretsky, J. A., & Neckers, L. (1995) · PubMed · Cited by 178
Mutant p53 mediates survival of breast cancer cells
Lim, L. Y., Vidnovic, N., Ellisen, L. W., & Leong, C.-O. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605335 · Cited by 175
Goldstein, I., Marcel, V, Olivier, M., Oren, M., Rotter, V, & Hainaut, P. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2010.63 · Cited by 167
Limiting the power of p53 through the ubiquitin proteasome pathway
Pant, V., & Lozano, G. (2014) · Genes & Development · doi:10.1101/gad.247452.114 · Cited by 167
Martin, L., Grigoryan, A., Wang, D., Wang, J., Breda, L., Rivella, S., Cardozo, T., & Gardner, L. B. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2235 · Cited by 165
Mutant p53 reactivation by small molecules makes its way to the clinic
Bykov, V. J. N., & Wiman, K. G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.04.017 · Cited by 162
CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death
Wischhusen, J., Naumann, U., Ohgaki, H., Rastinejad, F., & Weller, M. (2003) · Oncogene · doi:10.1038/sj.onc.1207198 · Cited by 158
Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
Yan, W., Liu, S., Xu, E., Zhang, J., Zhang, Y., Chen, X., & Chen, X. (2013) · Oncogene · doi:10.1038/onc.2012.81 · Cited by 153
Mechanism of rescue of common p53 cancer mutations by second‐site suppressor mutations
Nikolova, P. V., Wong, K., DeDecker, B., Henckel, J., & Fersht, A. R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.3.370 · Cited by 152
Characterization of the p53-rescue drug CP-31398 in vitro and in living cells
Rippin, T. M., Bykov, V. J. N., Freund, S. M. V., Selivanova, G., Wiman, K. G., & Fersht, A. R. (2002) · Oncogene · doi:10.1038/sj.onc.1205362 · Cited by 151
Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides
Floquet, C., Deforges, J., Rousset, J.-P., & Bidou, L. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1277 · Cited by 144
Egorin, M. J., Rosen, D. M., Wolff, J., Callery, P. S., Musser, S. M., & Eiseman, J. L. (1998) · PubMed · Cited by 133
A temperature‐sensitive mutant of human p53.
Zhang, W., Guo, X. Y., Hu, G., Liu, W. B., Shay, J. W., & Deisseroth, A. B. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06543.x · Cited by 127
Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for Efficient Apoptosis
Grinkevich, V. V., Nikulenkov, F., Shi, Y., Enge, M., Bao, W., Malyukova, A., Gluch, A., Kel, A. E., Sangfelt, O., & Selivanova, G. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.021 · Cited by 127
Karlsson, R., Kullman-Magnusson, M., Hämäläinen, M., Remaeus, A., Andersson, K., Borg, P., Gyzander, E., & Deinum, J. (2000) · Analytical Biochemistry · doi:10.1006/abio.1999.4406 · Cited by 126
Tang, X., Zhu, Y., Han, L., Kim, A. L., Kopelovich, L., Bickers, D. R., & Athar, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32481 · Cited by 124
Masciarelli, S., Fontemaggi, G., Di Agostino, S., Donzelli, S., Carcarino, E., Strano, S., & Blandino, G. (2014) · Oncogene · doi:10.1038/onc.2013.106 · Cited by 118
Zandi, R., Selivanova, G., Christensen, C. L., Gerds, T. A., Willumsen, B. M., & Poulsen, H. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3168 · Cited by 118
Puca, R., Nardinocchi, L., Porru, M., Simon, A. J., Rechavi, G., Leonetti, C., Givol, D., & D’Orazi, G. (2011) · Cell Cycle · doi:10.4161/cc.10.10.15642 · Cited by 117
Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis
Lambert, J. M. R., Moshfegh, A., Hainaut, P. L., Wiman, K. G., & Bykov, V. J. N. (2009) · Oncogene · doi:10.1038/onc.2009.425 · Cited by 112
Zhang, S., Zhou, L., Hong, B., van den Heuvel, A. P. J., Prabhu, V. V., Warfel, N. A., Kline, C. L. B., Dicker, D. T., Kopelovich, L., & El‐Deiry, W. S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-13-1079 · Cited by 111
Ramalingam, S. S., Goss, G. D., Rosell, R., Schmid‐Bindert, G., Zarić, B., Andric, Z. G., Bondarenko, I., Комов, Д. В., Cerić, T., Khuri, F. R., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv220 · Cited by 111
The pharmacology and toxicology of disulfiram and its metabolites
Petersen, E. N. (1992) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1992.tb03309.x · Cited by 110
Blagosklonny, M. V. (2005) · Cell Cycle · doi:10.4161/cc.4.12.2259 · Cited by 110
Jhaveri, K. L., Chandarlapaty, S., Lake, D. E., Gilewski, T. A., Robson, M. E., Goldfarb, S. B., Drullinsky, P. R., Sugarman, S. M., Wasserheit, C., Fasano, J., et al. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.12.012 · Cited by 108
Weinmann, L., Wischhusen, J., Demma, M. J., Naumann, U., Roth, P., Dasmahapatra, B., & Weller, M. (2008) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402301 · Cited by 108
Demma, M. J., Maxwell, E., Ramos, R., Liang, L., Li, C., Hesk, D., Rossman, R. R., Mallams, A. K., Doll, R. J., Liu, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.083469 · Cited by 107
Kessler, J., Hahnel, A., Wichmann, H., Rot, S., Kappler, M., Bache, M., & Vordermark, D. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-605 · Cited by 103
Yu, X., Blanden, A. R., Narayanan, S., Jayakumar, L., Lubin, D., Augeri, D., David Kimball, S., Loh, S. N., & Carpizo, D. R. (2014) · Oncotarget · doi:10.18632/oncotarget.2432 · Cited by 102
Micale, L., Augello, B., Maffeo, C., Selicorni, A., Zucchetti, F., Fusco, C., Nittis, P. D., Pellico, M. T., Mandriani, B., Fischetto, R., et al. (2014) · Human Mutation · doi:10.1002/humu.22547 · Cited by 102
Yi, Y. W., Kang, H. J., Kim, H. J., Kong, Y., Brown, M. L., & Bae, I. (2013) · Oncotarget · doi:10.18632/oncotarget.1070 · Cited by 96
Mutant p53 targeting by the low molecular weight compound STIMA‐1
Zache, N., Lambert, J. M. R., Rökaeus, N., Shen, J., Hainaut, P., Bergman, J., Wiman, K. G., & Bykov, V. J. N. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.02.004 · Cited by 96
Reguart, N., Rosell, R., Cardenal, F., Cardona, A. F., Isla, D., Palmero, R., Morán, T., Rolfo, C. D., Pallarès, M. C., Insa, A., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.02.011 · Cited by 95
Identification of potential synthetic lethal genes to p53 using a computational biology approach
Wang, X., & Simon, R. (2013) · BMC Medical Genomics · doi:10.1186/1755-8794-6-30 · Cited by 93
Staab, A., Loeffler, J., Said, H. M., Diehlmann, D., Katzer, A., Beyer, M., Fleischer, M., Schwab, F., Baier, K., Einsele, H., et al. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-213 · Cited by 89
Gu, H.-Y., Wang, X., Rao, S., Wang, J., Zhao, J., Ren, F. L., Mu, R., Yang, Y., Qi, Q., Liu, W., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0212 · Cited by 84
González, M. V., Pello, M. F., López‐Larrea, C., Suarez, C. M., Menéndez, M., & Coto, E. (1995) · PubMed · Cited by 82
Hiraki, M., Hwang, S.-Y., Cao, S., Ramadhar, T. R., Byun, S., Yoon, K. W., Lee, J. H., Chu, K., Gurkar, A. U., Kolev, V., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.07.016 · Cited by 81
Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA
Zhao, C. Y., Grinkevich, V., Nikulenkov, F., Bao, W., & Selivanova, G. (2010) · Cell Cycle · doi:10.4161/cc.9.9.11545 · Cited by 79
Blanden, A. R., Yu, X., Wolfe, A. J., Gilleran, J. A., Augeri, D. J., O’Dell, R. S., Olson, E. C., Kimball, S. D., Emge, T. J., Movileanu, L., et al. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.097550 · Cited by 79
Yanada, M., Tsuzuki, M., Fujita, H., Fujimaki, K., Fujisawa, S., Sunami, K., Taniwaki, M., Ohwada, A., Tsuboi, K., Maeda, A., et al. (2013) · Blood · doi:10.1182/blood-2012-11-466862 · Cited by 78
Efficace, F., Mandelli, F., Avvisati, G., Cottone, F., Ferrara, F., Bona, E. D., Specchia, G., Breccia, M., Levis, A., Sica, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.3453 · Cited by 78
Phosphorylation and hsp90 Binding Mediate Heat Shock Stabilization of p53
Wang, C., & Chen, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m206697200 · Cited by 76
North, S., Pluquet, O., Maurici, D., Ghissassi, F. E., & Hainaut, P. L. (2002) · Molecular Carcinogenesis · doi:10.1002/mc.10038 · Cited by 75
PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein
Hyder (2009) · International Journal of Oncology · doi:10.3892/ijo_00000416 · Cited by 74
Yan, W., Zhang, Y., Jin, Z., Liu, S., Cho, S. J., & Chen, X. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.231639 · Cited by 71
Regular surveillance for Li-fraumeni syndrome: advice, adherence and perceived benefits
Lammens, C. R. M., Bleiker, E. M. A., Aaronson, N. K., Wagner, A., Sijmons, R. H., Ausems, M. G. E. M., Vriends, A. H. J. T., Ruijs, M., van Os, T. A. M., Spruijt, L., et al. (2010) · Familial Cancer · doi:10.1007/s10689-010-9368-z · Cited by 70
Nieves‐Neira, W., Rivera, M. I., Kohlhagen, G., Hursey, M. L., Pourquier, P., Sausville, E. A., & Pommier, Y. G. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.3.478 · Cited by 70
Gambogic acid‐induced degradation of mutant p53 is mediated by proteasome and related to CHIP
Wang, J., Zhao, Q. J., Qi, Q., Gu, H.-Y., Rong, J., Mu, R., Zou, M., Tao, L., You, Q., & Guo, Q. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22941 · Cited by 69
Zhu, H., Yang, K. G., Xie, Y.-Q., Lin, Y.-W., Mao, Q., & Xie, L. (2013) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-11-22 · Cited by 69
PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
(2008) · PubMed Central · doi:10.3233/clo-2008-0440 · Cited by 68
Reactivation of mutant p53: a new strategy for cancer therapy
Selivanova, G., Kawasaki, T., Ryabchenko, L. G., & Wiman, K. G. (1998) · Seminars in Cancer Biology · doi:10.1006/scbi.1998.0099 · Cited by 63
Burmakin, M., Shi, Y., Hedström, E., Kogner, P., & Selivanova, G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2211 · Cited by 63
p53 orchestrates between normal differentiation and cancer
Rivlin, N., Koifman, G., & Rotter, V. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.006 · Cited by 62
Kona, F. R., Buac, D., & Burger, A. M. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911794519798 · Cited by 59
Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function
Margalit, O., Simon, A. J., Yakubov, E., Puca, R., Yosepovich, A., Avivi, C., Jacob‐Hirsch, J., Gelernter, I., Harmelin, A., Barshack, I., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26441 · Cited by 58
Yan, W., Jung, Y.-S., Zhang, Y., & Chen, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103497 · Cited by 55
Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines
Rivera, M. I., Stinson, S. F., Vistica, D. T., Jorden, J. L., Kenney, S., & Sausville, E. A. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00046-5 · Cited by 54
A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma
Goyal, L., Wadlow, R. C., Blaszkowsky, L. S., Wolpin, B. M., Abrams, T. A., McCleary, N. J., Sheehan, S., Sundaram, E., Karol, M. D., Chen, J. L., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0164-8 · Cited by 50
Pluquet, O., North, S., Bhoumik, A., DIMAS, K. S., Ronai, Z. A., & Hainaut, P. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207396200 · Cited by 49
Molecular genetics of human cancer predisposition and progression
Cavenee, W. K., Scrable, H. J., & James, C. D. (1991) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(91)90015-g · Cited by 48
Jiang, W., Wang, X. W., Unger, T., Forgues, M., Kim, J. W., Hussain, S. P., Bowman, E. D., Spillare, E. A., Lipsky, M. M., Meck, J. M., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.25118 · Cited by 47
Yusuf, M. A., Chuang, T. L., Bhat, G. J., & Srivenugopal, K. S. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.06.020 · Cited by 46
Effects of pesticide chemicals on the activity of metabolic enzymes: focus on thiocarbamates
Mathieu, C., Duval, R., Xu, X., Rodrigues‐Lima, F., & Dupret, J. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.975691 · Cited by 45
A Randomized Phase II Study of Cisplatin Alone Versus Cisplatin Plus Disulfiram
Verma, S., Stewart, D. J., Maroun, J. A., & Nair, R. C. (1990) · American Journal of Clinical Oncology · doi:10.1097/00000421-199004000-00007 · Cited by 44
Shen, H., Chen, Z. J., Zilfou, J. T., Hopper-Borge, E. A., Murphy, M. E., & Tew, K. D. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29634-8 · Cited by 44
The p53-Mdm2 Loop: A Critical Juncture of Stress Response
Levav-Cohen, Y., Goldberg, Z., Tan, K. H., Alsheich-Bartok, O., Zuckerman, V., Haupt, S., & Haupt, Y. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_9 · Cited by 43
Saha, M. N., Chen, Y., Chen, M.-H., Chen, G., & Chang, H. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.164 · Cited by 43
Paranjpe, A. S., & Srivenugopal, K. S. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt032 · Cited by 39
Liu, W.-L., Midgley, C., Stephen, C. W., Saville, M. K., & Lane, D. P. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.5082 · Cited by 38
Pluquet, O., North, S., Richard, M., & Hainaut, P. L. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01655-6 · Cited by 35
Tanner, S., & Barberis, A. (2004) · Journal of Negative Results in BioMedicine · doi:10.1186/1477-5751-3-5 · Cited by 33
Shimoyama, S. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1583-2 · Cited by 32
Beauchamp, E. M., & Üren, A. (2012) · Vitamins and hormones · doi:10.1016/b978-0-12-394622-5.00015-8 · Cited by 30
Yoo, C., Ryu, M., Na, Y.-S., Ryoo, B., Lee, C.-W., Maeng, J., Kim, S.-Y., Koo, D., Park, I., & Kang, Y. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9983-2 · Cited by 26
Pintus, S. S., Ivanisenko, N. V., Сергеевич, Д. П., Ivanisenko, T., Ramachandran, S., Kolchanov, N. A., & Иванисенко, В. А. (2012) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2012.691364 · Cited by 19
Zhu, H., Mao, Q., Lin, Y., Yang, K. G., & Xie, L. (2010) · Medical Oncology · doi:10.1007/s12032-010-9679-9 · Cited by 19
Rao, C. V., Patlolla, J. M. R., Qian, L., Zhang, Y., Brewer, M. F., Mohammed, A., Desai, D. H., Amin, S., Lightfoot, S. A., & Kopelovich, L. (2013) · Neoplasia · doi:10.1593/neo.131256 · Cited by 18
[Synthetic lethal genes to mutant p53].
Liu, T.-Y., Guo, H.-Q., Zhu, M., Huang, Y., Jia, S., Luo, Y., & Zhang, J. (2015) · PubMed · doi:10.16288/j.yczz.14-277 · Cited by 5
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
Encyclopedia of Inorganic and Bioinorganic Chemistry
(2011) · Wiley eBooks · doi:10.1002/9781119951438 · Cited by 1,585
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494
Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer
Liu, G., Pei, F., Yang, F., Li, L., Amin, A., Liu, S., Buchan, J., & Cho, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020367 · Cited by 425
Metadata
- Authors
- Parrales, A., & Iwakuma, T.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2015-12-21
- Volume
- 5
- Pages
- 288-288
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2210624024
- Cited by
- 337
- References
- 128
- FWCI
- 12.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.